Categories: News

NetNoggin® research to be presented at the 2019 Alzheimer’s Association International Conference

FREDERICK, Md., April 4, 2019 /PRNewswire/ — NetNoggin® announced they will present additional findings from their Alzheimer’s disease research report at the upcoming Alzheimer’s Association International Conference (AAIC®).

“We are ecstatic to be joining leading developers and researchers to share research, discoveries, and next-generation ideas to improve the lives of patients with Alzheimer’s and their caregivers,” said Diana Conger, CEO of NetNoggin®. “This conference helps us achieve our mission: inspiring healthcare solutions to improve patients’ quality of life.”

NetNoggin® entered the Alzheimer’s disease-space when they published their most recent syndicated report, NetNog: #genesis® Alzheimer’s Disease (including MCI), in 2018. On Sunday July 14th and Monday July 15th, at the Los Angeles Convention Center, NetNoggin® will present additional findings outside of the scope of their published research report. 

About NetNog: #genesis®
NetNog: #genesis® is foundational research that (1) brings patient voice to the development process and (2) identifies gaps and areas for improvement in the marketplace. NetNoggin‘s vision is to disrupt the way pharmaceutical companies do market research by providing a holistic understanding of patients and caregivers sooner. The research is grounded in netnography and supported with secondary research to provide context.  

Visit https://netnoggin.net/disease-focused-research to learn more about NetNog: #genesis®.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops. NetNoggin® was established in 2011. The founder, Diana Conger, has been involved in bringing over 20 pharmaceutical products to market and has in-depth knowledge of over 50 disease-states.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-research-to-be-presented-at-the-2019-alzheimers-association-international-conference-300824394.html

SOURCE NetNoggin, LLC

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

52 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

53 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

56 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

56 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

56 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

57 minutes ago